AVIR - Atea Pharmaceuticals Inc Stock Price, Fair Value and News

$2.89+0.04 (+1.40%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AVIR Price Action

Last 7 days

5.5%

Last 30 days

1.4%

Last 90 days

-6.5%

Trailing 12 Months

-21.7%

AVIR RSI Chart

AVIR Valuation

Market Cap

247.3M

Price/Earnings (Trailing)

-1.77

Price/Sales (Trailing)

9.7

EV/EBITDA

-0.93

Price/Free Cashflow

-1.96

AVIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AVIR Fundamentals

AVIR Revenue

Revenue (TTM)

25.5M

Rev. Growth (Yr)

-27.61%

Rev. Growth (Qtr)

-14.34%

AVIR Earnings

Earnings (TTM)

-139.5M

Earnings Growth (Yr)

45.75%

Earnings Growth (Qtr)

-2.17%

AVIR Profitability

EBT Margin

-543.71%

Return on Equity

-33.93%

Return on Assets

-31.7%

Free Cashflow Yield

-51.02%

AVIR Investor Care

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-1.65

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	35.0M	35.4M	0	25.5M
2023	158.1M	93.7M	0	29.2M
2022	286.9M	222.5M	0	0
2021	124.3M	200.0M	275.7M	351.4M
2020	0	0	0	48.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CEO	Dr. Jean-Pierre Sommadossi Ph.D.
WEBSITE	https://ateapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	72

Atea Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Atea Pharmaceuticals Inc? What does AVIR stand for in stocks?

AVIR is the stock ticker symbol of Atea Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atea Pharmaceuticals Inc (AVIR)?

As of Fri May 23 2025, market cap of Atea Pharmaceuticals Inc is 247.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers.

Is Atea Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AVIR is over valued or under valued. Whether Atea Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Atea Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVIR.

What is Atea Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 23 2025, AVIR's PE ratio (Price to Earnings) is -1.77 and Price to Sales (PS) ratio is 9.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVIR PE ratio will change depending on the future growth rate expectations of investors.